NCT03646994View on ClinicalTrials.gov

Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer

RecruitingOBSERVATIONAL

Enrollment

40

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

December 31, 2024

Study Completion Date

December 1, 2025

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Crizotinib

Crizotinib Cap 250 mg po bid

Trial Locations (1)

410013

RECRUITING

Hunan Cancer Hospital, Changsha

All Listed Sponsors

lead

Hunan Province Tumor Hospital

OTHER